Impact of New Generation Hormono-therapy on Cognitive Functions in Elderly Patients Treated for a Metastatic Prostate Cancer

Inclusion Criteria:

For the group of patients of interest :

* Patient must have a metastatic castration-resistant prostate cancer (CRPCa)
* Patient must be 70 years and more
* Performance Status 0-2
* Patient must have not received chemotherapy except one line per Docetaxel for hormono-sensitive situation and which must be completed for a least 18 months before inclusion
* Patient must have been already treated with first generation of androgen deprivation therapy
* Patient must be asymptomatic or pauci-symptomatic (with pain control, Visual Analog Scale ≤ 3)
* Patient must be candidate for a treatment by a new generation hormono-therapy (with abiraterone acetate or enzalutamide), in accordance to precautions of these treatments described in Summary Characteristics of Product and in combination with androgen deprivation therapy
* Treatment with biphosphonates is authorized
* No known brain metastasis
* Patient must be at least on level 3 on school scale
* Patient has signed informed consent

For the control group of patients :

* Patient with metastatic prostate cancer without resistance to castration
* Patient must be 70 years and more
* Performance Status 0-2
* Patient must have not received chemotherapy except one line per Docetaxel for hormono-sensitive situation and which must be completed for a least 18 months before inclusion
* Patient must have already started the first generation of androgen deprivation therapy at least since 3 months
* Patient must be asymptomatic or pauci-symptomatic (with pain control, Visual Analog Scale ≤ 3)
* No known brain metastasis
* Patient must be at least on level 3 on school scale
* Patient has signed informed consent

For the control group of healthy volunteers:

* Man
* No history of cancer,
* 70-year old or more,
* Health status consistent with the participation to the study
* At least on level 3 on school scale
* Signed informed consent

Exclusion Criteria:

For all participants (group of patients of interest, control group of patients and group of healthy volunteers):

* No previous treatment with a new generation hormone therapy (abiraterone acetate or enzalutamide)
* Neurological sequelae of (traumatic brain injury, stroke, multiple sclerosis, epilepsy, neuro-degenerative disease…)
* Known evolutive psychiatric disorder
* Drug use
* Heavy drinking
* Assessed to be unable or unwilling to comply with the requirements of the protocol

For group of patients of interest, additional non-inclusion criteria :

* Hypersensitivity to abiraterone acetate or enzalutamide
* For patients candidate for abiraterone acetate, presence of severe hepatic insufficiency